Skip to main content
Premium Trial:

Request an Annual Quote

Clarified Precision Medicine Raises $1.2M in Seed Round

NEW YORK – Clarified Precision Medicine on Tuesday said it has raised $1.2 million in a seed financing round, which it will put toward advancing its virtual molecular tumor board model and help more patients and providers gain access to guidelines-based precision oncology treatments.

San Francisco-based Clarified is commercializing a model that uses machine learning to analyze next-generation sequencing test results for cancer patients and identify potentially actionable insights. Then, Clarified's network of precision oncology experts review the insights from the platform and recommend treatments for patients. 

Avestria Ventures led the financing round and Joyance Partners participated. Also on Tuesday, Clarified appointed Rajni Natesan as CEO.

An estimated 75 percent of doctors say they need help interpreting patients' genomic test results. At Clarified, the aim is to use machine learning and knowledgeable physicians to provide community oncologists the level of precision oncology expertise typically available at comprehensive cancer centers and leading academic institutions.

Clarified has a platform dubbed OncoGuardian, which it acquired in 2021 when it bought Interpares Biomedicine, which analyzes patients' sequencing results to determine their likelihood of experiencing extreme toxicities from immune checkpoint inhibitors.

The firm also operates the ClarifiedSelect platform, which provides a ranked, expert-reviewed list of treatment options for each patient based on their genomic profiling results.

Clarified is establishing flexible payment options, including direct insurance billing, as it commercializes its services.